178 related articles for article (PubMed ID: 27041935)
1. The pathology of unusual subtypes of prostate cancer.
Li J; Wang Z
Chin J Cancer Res; 2016 Feb; 28(1):130-43. PubMed ID: 27041935
[TBL] [Abstract][Full Text] [Related]
2. Foamy gland variant of prostate adenocarcinoma.
Madakshira MG
Med J Armed Forces India; 2023; 79(2):241-243. PubMed ID: 36969122
[No Abstract] [Full Text] [Related]
3. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.
Lee JK; Phillips JW; Smith BA; Park JW; Stoyanova T; McCaffrey EF; Baertsch R; Sokolov A; Meyerowitz JG; Mathis C; Cheng D; Stuart JM; Shokat KM; Gustafson WC; Huang J; Witte ON
Cancer Cell; 2016 Apr; 29(4):536-547. PubMed ID: 27050099
[TBL] [Abstract][Full Text] [Related]
4. Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer.
Carver BS
Cancer Cell; 2016 Apr; 29(4):431-432. PubMed ID: 27070695
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer is not breast cancer.
Venniyoor A
Indian J Med Paediatr Oncol; 2016; 37(1):4-5. PubMed ID: 27051149
[TBL] [Abstract][Full Text] [Related]
6. Management and therapeutic response of a prostate ductal adenocarcinoma: a still unknown tumour?
Martorana E; Micali S; Pirola GM; Reggiani Bonetti L; Clò V; Ghaith A; Bianchi G
Urologia; 2016 Sep; 83(3):163-167. PubMed ID: 27174534
[TBL] [Abstract][Full Text] [Related]
7. The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer.
Onstenk W; de Klaver W; de Wit R; Lolkema M; Foekens J; Sleijfer S
Cancer Treat Rev; 2016 May; 46():42-50. PubMed ID: 27107266
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
Luo J; Beer TM; Graff JN
Oncology (Williston Park); 2016 Apr; 30(4):336-44. PubMed ID: 27085332
[TBL] [Abstract][Full Text] [Related]
9. Small cell carcinoma of the prostate presenting with Cushing Syndrome. A narrative review of an uncommon condition.
Rueda-Camino JA; Losada-Vila B; De Ancos-Aracil CL; Rodríguez-Lajusticia L; Tardío JC; Zapatero-Gaviria A
Ann Med; 2016; 48(4):293-9. PubMed ID: 27068390
[TBL] [Abstract][Full Text] [Related]
10. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
11. Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer.
Yadav KK; Shameer K; Readhead B; Yadav SS; Li L; Kasarskis A; Tewari AK; Dudley JT
Curr Pharm Des; 2016; 22(34):5234-5248. PubMed ID: 27174811
[TBL] [Abstract][Full Text] [Related]
12. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.
Rahbar K; Bode A; Weckesser M; Avramovic N; Claesener M; Stegger L; Bögemann M
Clin Nucl Med; 2016 Jul; 41(7):522-8. PubMed ID: 27088387
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-PSMA PET/CT Imaging and 153Sm-EDTMP Bone Pain Palliation Therapy.
Sasikumar A; Joy A; Nanabala R; Pillai MR; Thomas B
Clin Nucl Med; 2016 Jul; 41(7):e353-4. PubMed ID: 27055142
[TBL] [Abstract][Full Text] [Related]
14. Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.
El-Amm J; Aragon-Ching JB
Clin Med Insights Oncol; 2016; 10(Suppl 1):11-9. PubMed ID: 27042152
[TBL] [Abstract][Full Text] [Related]
15. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.
Fu AZ; Tsai HT; Haque R; Ulcickas Yood M; Van Den Eeden SK; Cassidy-Bushrow AE; Zhou Y; Keating NL; Smith MR; Aaronson DS; Potosky AL
World J Urol; 2016 Dec; 34(12):1611-1619. PubMed ID: 27084777
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer.
Tyson MD; Arora SS; Scarpato KR; Barocas D
Urol Oncol; 2016 Jul; 34(7):326-32. PubMed ID: 27083114
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature.
Zilli T; Dal Pra A; Kountouri M; Miralbell R
Cancer Treat Rev; 2016 May; 46():35-41. PubMed ID: 27082769
[TBL] [Abstract][Full Text] [Related]
18. MYCN Transforms Prostate Epithelium to Neuroendocrine Prostate Cancer.
Cancer Discov; 2016 Jun; 6(6):OF19. PubMed ID: 27080339
[TBL] [Abstract][Full Text] [Related]
19. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
[TBL] [Abstract][Full Text] [Related]
20. Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review.
Rahal AK; Badgett RG; Hoffman RM
PLoS One; 2016; 11(4):e0153417. PubMed ID: 27070904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
